Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918433 | 0.85 | TACR1 (0.38) | TACR1CETP | |
| SCHEMBL3224312 | 0.85 | TACR1 (0.38) | TACR1CETP | |
| SCHEMBL1600392 | 0.84 | CETP (0.42) | TACR1CETP | |
| SCHEMBL3217676 | 0.81 | CETP (0.40) | TACR1CETP | |
| SCHEMBL3582626 | 0.81 | CETP (0.36) | TACR1CETP | |
| SCHEMBL14470856 | 0.80 | CETP (0.39) | TACR1CETP | |
| SCHEMBL3576572 | 0.80 | CETP (0.39) | TACR1CETP | |
| SCHEMBL3215672 | 0.80 | CETP (0.41) | CETP | |
| SCHEMBL3198681 | 0.79 | CETP (0.39) | CETP | |
| SCHEMBL1601013 | 0.78 | CETP (0.45) | TACR1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076021-A1 | Organic Compounds | IMASE HIDETOMO | 2010-03-25 | — | — | US | disclosed |
| US-20100076021-A1 | Organic Compounds | IMASE HIDETOMO | 2010-03-25 | — | — | US | disclosed |
| US-20100076021-A1 | Organic Compounds | IMASE HIDETOMO | 2010-03-25 | — | — | US | disclosed |
| US-20100041705-A1 | Organic Compounds | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041705-A1 | Organic Compounds | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041705-A1 | Organic Compounds | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| CN-101600708-A | Organic compound | NOVARTIS AG (CH) | 2009-12-09 | — | — | CN | disclosed |
| EP-2086961-A1 | HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| EP-2084149-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008058961-A1 | HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008058961-A1 | HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008058967-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008058967-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076021-A1 | Organic Compounds | CETP, NPC1, LCAT | TACR1 1439/4885CETP 1/4885 |
| US-20100041705-A1 | Organic Compounds | CETP, NPC1, LCAT | TACR1 1439/4885CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.